The approval from the United States Food and Drug Administration (USFDA) is for the company's abbreviated new drug application (ANDA) for Doxycycline Hyclate capsules USP, in the strengths of 50 mg and 100 mg, Alembic Pharmaceuticals said in a filing to BSE.
The product is generic version of Pfizer Inc's Vibramycin capsules in the same strengths, it added.
The company currently has a total of 73 ANDA approvals (65 final approvals and 8 tentative approvals) from USFDA, it added.
Shares of Alembic Pharmaceuticals today closed at Rs 506.55 per scrip on BSE, up 3.32 per cent from its previous close.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)